Ranexa: For Patients Who Have Not Achieved an Adequate Response With Other Antianginal Drugs†
 |
Inadequate response to treatment
- 58 years old
- Post-revascularization, on a beta-blocker and nitrate
- Unsuccessfully tried on calcium channel blockers
|
| |
|
 |
Comorbidities limit his options
- 64 years old
- CHF, hypertension
- Refuses
revascularization,
on a
beta-blocker
- History of severe
headaches
|
| |
|
 |
Comorbidities limit her options
- 72 years old
- Post-MI, poor candidate
for revascularization, on a
beta-blocker
- Bradycardia,
diabetes mellitus
- History of ankle edema
|
| †The effect of Ranexa on angina rate or exercise tolerance appeared to be smaller in
women than men. |
| |
|
 |
Inadequate response to treatment
- 82 years old
- Reactive airway
disease
- On amlodipine
|
| A higher incidence of adverse events was observed in elderly (≥75 years) patients on
Ranexa. |
Ranexa is contraindicated in patients with pre-existing
QT prolongation; with hepatic impairment (mild,
moderate, or severe); on QT-prolonging drugs; on
potent and moderately potent CYP3A inhibitors,
including diltiazem.
|
